Literature DB >> 2036731

Management of prolactinomas.

D Cunnah1, M Besser.   

Abstract

The management of prolactinomas requires a complex interaction of medical, surgical and radiotherapeutic intervention. With the judicious use of all these modalities, patients can usually be managed with great success and, perhaps more importantly, their presenting complaints (gonadal dysfunction and infertility) are usually completely corrected.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2036731     DOI： 10.1111/j.1365-2265.1991.tb00299.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN： 0300-0664            Impact factor:   3.478


  17 in total

1.  Agonist-induced endocytosis and receptor phosphorylation mediate resensitization of dopamine D(2) receptors.

Authors:  Dongim Cho; Mei Zheng; Chengchun Min; Lan Ma; Hitoshi Kurose; Jae H Park; Kyeong-Man Kim
Journal:  Mol Endocrinol       Date:  2010-02-16

Review 2.  Growth factors in the pathogenesis of prolactin-secreting tumors.

Authors:  C Missale; P F Spano
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

3.  Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.

Authors:  Robert R Luedtke; Yogesh Mishra; Qi Wang; Suzy A Griffin; Cathy Bell-Horner; Michelle Taylor; Suwanna Vangveravong; Glenn H Dillon; Ren-Qi Huang; David E Reichert; Robert H Mach
Journal:  ACS Chem Neurosci       Date:  2012-10-12       Impact factor: 4.418

4.  ARF6 and GASP-1 are post-endocytic sorting proteins selectively involved in the intracellular trafficking of dopamine D₂ receptors mediated by GRK and PKC in transfected cells.

Authors:  D I Cho; M Zheng; C Min; K J Kwon; C Y Shin; H K Choi; K M Kim
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

5.  Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626.

Authors:  Suwanna Vangveravong; Michelle Taylor; Jinbin Xu; Jinquan Cui; Wesley Calvin; Sonja Babic; Robert R Luedtke; Robert H Mach
Journal:  Bioorg Med Chem       Date:  2010-05-24       Impact factor: 3.641

6.  Falsely low serum prolactin in two cases of invasive macroprolactinoma.

Authors:  Christof Schöfl; Beate Schöfl-Siegert; Johann Hinrich Karstens; Michael Bremer; Thomas Lenarz; Jose Sebastian Fernandez Cuarezma; Madjid Samii; Alexander von zur Mühlen; Georg Brabant
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

7.  Dopaminergic resistance in a case of invasive macroprolactinoma.

Authors:  D Schwarzstein; A García-Patterson; G Giménez; J Calaf; M Puig-Domingo; A Caixàs; X Matías-Guiu; S M Webb
Journal:  J Endocrinol Invest       Date:  1993-06       Impact factor: 4.256

8.  Nerve growth factor suppresses the transforming phenotype of human prolactinomas.

Authors:  C Missale; F Boroni; M Losa; M Giovanelli; A Zanellato; R Dal Toso; A Balsari; P Spano
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

9.  Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways.

Authors:  Michelle Taylor; Peter Grundt; Suzy A Griffin; Amy Hauck Newman; Robert R Luedtke
Journal:  Synapse       Date:  2010-03       Impact factor: 2.562

10.  Prolactin secreting pituitary carcinoma.

Authors:  T Petterson; I A MacFarlane; J M MacKenzie; M D Shaw
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.